Edict Acquisition (Edict Acquisition [Member])

12 Months Ended

Dec. 31, 2014

Edict Acquisition [Member]

Business Acquisition [Line Items]

Acquisition

Edict Acquisition:

On February 17, 2012, through Par Pharmaceutical, Inc., our wholly-owned subsidiary, we completed our acquisition of privately-held Edict Pharmaceuticals Private Limited, which has been renamed Par Formulations Private Limited (referred to as “Par Formulations”), for cash and our repayment of certain additional pre-close indebtedness (the “Edict Acquisition”).  The operating results of Par Formulations were included in our consolidated financial results from the date of acquisition.  The operating results were reflected as part of the Par Pharmaceutical segment.  We funded the purchase from cash on hand. 

The addition of Par Formulations broadened our industry expertise and expanded our research & development and manufacturing capabilities.  The Edict Acquisition was revalued as part of the business combination accounting for the Merger. Refer to Note 2 - “Sky Growth Merger.”